Elanco Animal Health Incorporated (NYSE:ELAN) Receives $23.78 Average Target Price from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $25.1111.

ELAN has been the topic of a number of recent analyst reports. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $24.00 to $30.00 in a report on Thursday. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Wednesday, December 10th. Morgan Stanley raised their price target on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, December 18th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th.

Insiders Place Their Bets

In other Elanco Animal Health news, insider Rajeev A. Modi purchased 4,500 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the transaction, the insider owned 123,082 shares in the company, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the transaction, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have bought 43,450 shares of company stock worth $937,883. Insiders own 0.89% of the company’s stock.

Institutional Trading of Elanco Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC raised its stake in Elanco Animal Health by 434.2% in the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock worth $1,801,000 after buying an additional 102,686 shares in the last quarter. Norges Bank bought a new stake in Elanco Animal Health during the 2nd quarter valued at approximately $12,502,000. Yousif Capital Management LLC grew its holdings in shares of Elanco Animal Health by 1,333.7% during the 3rd quarter. Yousif Capital Management LLC now owns 168,133 shares of the company’s stock worth $3,386,000 after acquiring an additional 156,406 shares during the period. Equitable Trust Co. raised its position in shares of Elanco Animal Health by 65.5% in the 2nd quarter. Equitable Trust Co. now owns 248,108 shares of the company’s stock worth $3,543,000 after acquiring an additional 98,172 shares in the last quarter. Finally, Amalgamated Bank raised its position in shares of Elanco Animal Health by 793.7% in the 3rd quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after acquiring an additional 201,226 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 2.5%

NYSE:ELAN opened at $24.91 on Tuesday. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $25.29. The stock’s fifty day moving average price is $22.68 and its two-hundred day moving average price is $19.91. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The company has a market cap of $12.38 billion, a P/E ratio of 415.24, a P/E/G ratio of 3.38 and a beta of 1.87.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.13 EPS. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.